Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling

Guochun Jiang, Erica A. Mendes, Philip Keiser, Sumathi Sankaran-Walters, Yuyang Tang, Mariana G. Weber, Greg P. Melcher, George R. Thompson, Amilcar Tanuri, Luiz F. Pianowski, Joseph K. Wong, Satya Dandekar

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective: Although HAART effectively suppresses viral replication, it fails to eradicate latent viral reservoirs. The 'shock and kill' strategy involves the activation of HIV from latent reservoirs and targeting them for eradication. Our goal was to develop new approaches for activating HIV from latent reservoirs. Design: We investigated capacity of Ingenol B (IngB), a newly modified derivative of Ingenol ester that was originally isolated from a Brazilian plant in Amazon, for its capacity and mechanisms of HIV reactivation. Methods: Reactivation of HIV-1 by IngB was evaluated in J-Lat A1 cell culture model of HIV latency as well as in purified primary CD4+ T cells from long-term HAART-treated virologically-suppressed HIV-infected individuals. The underlining molecular mechanisms of viral reactivation were investigated using flow cytometry, RT-qPCR and chromatin immunoprecipitation. Results: IngB is highly effective in reactivating HIV in J-Lat A1 cells with relatively low cellular toxicity. It is also able to reactivate latent HIV in purified CD4 + T cells from HAART-treated HIV-positive individuals ex vivo. Our data show that IngB may reactivate HIV expression by both activating protein kinase C (PKC)δ-nuclear factor kappalight- chain-enhancer of activated B cells (NF-κB) pathway and directly inducing NF-kB protein expression. Importantly, IngB has a synergistic effect with JQ1, a BET bromodomain inhibitor, in latent HIV reactivation. Conclusions: IngB is a new promising compound to activate latent HIV reservoirs. Our data suggest that formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.

Original languageEnglish (US)
Pages (from-to)1555-1566
Number of pages12
JournalAIDS
Volume28
Issue number11
DOIs
StatePublished - Jul 17 2014
Externally publishedYes

Fingerprint

Protein Kinase C
HIV
Highly Active Antiretroviral Therapy
ingenol
Esters
T-Lymphocytes
NF-kappa B
Chromatin Immunoprecipitation
HIV-1
Shock
Flow Cytometry
B-Lymphocytes
Cell Culture Techniques

Keywords

  • HIV latency
  • Ingenol ester
  • JQ1
  • NF-κB
  • Protein kinase C

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases
  • Medicine(all)

Cite this

Jiang, G., Mendes, E. A., Keiser, P., Sankaran-Walters, S., Tang, Y., Weber, M. G., ... Dandekar, S. (2014). Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS, 28(11), 1555-1566. https://doi.org/10.1097/QAD.0000000000000289

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. / Jiang, Guochun; Mendes, Erica A.; Keiser, Philip; Sankaran-Walters, Sumathi; Tang, Yuyang; Weber, Mariana G.; Melcher, Greg P.; Thompson, George R.; Tanuri, Amilcar; Pianowski, Luiz F.; Wong, Joseph K.; Dandekar, Satya.

In: AIDS, Vol. 28, No. 11, 17.07.2014, p. 1555-1566.

Research output: Contribution to journalArticle

Jiang, G, Mendes, EA, Keiser, P, Sankaran-Walters, S, Tang, Y, Weber, MG, Melcher, GP, Thompson, GR, Tanuri, A, Pianowski, LF, Wong, JK & Dandekar, S 2014, 'Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling', AIDS, vol. 28, no. 11, pp. 1555-1566. https://doi.org/10.1097/QAD.0000000000000289
Jiang, Guochun ; Mendes, Erica A. ; Keiser, Philip ; Sankaran-Walters, Sumathi ; Tang, Yuyang ; Weber, Mariana G. ; Melcher, Greg P. ; Thompson, George R. ; Tanuri, Amilcar ; Pianowski, Luiz F. ; Wong, Joseph K. ; Dandekar, Satya. / Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. In: AIDS. 2014 ; Vol. 28, No. 11. pp. 1555-1566.
@article{de93e296f8164473a65f422bf0807b28,
title = "Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling",
abstract = "Objective: Although HAART effectively suppresses viral replication, it fails to eradicate latent viral reservoirs. The 'shock and kill' strategy involves the activation of HIV from latent reservoirs and targeting them for eradication. Our goal was to develop new approaches for activating HIV from latent reservoirs. Design: We investigated capacity of Ingenol B (IngB), a newly modified derivative of Ingenol ester that was originally isolated from a Brazilian plant in Amazon, for its capacity and mechanisms of HIV reactivation. Methods: Reactivation of HIV-1 by IngB was evaluated in J-Lat A1 cell culture model of HIV latency as well as in purified primary CD4+ T cells from long-term HAART-treated virologically-suppressed HIV-infected individuals. The underlining molecular mechanisms of viral reactivation were investigated using flow cytometry, RT-qPCR and chromatin immunoprecipitation. Results: IngB is highly effective in reactivating HIV in J-Lat A1 cells with relatively low cellular toxicity. It is also able to reactivate latent HIV in purified CD4 + T cells from HAART-treated HIV-positive individuals ex vivo. Our data show that IngB may reactivate HIV expression by both activating protein kinase C (PKC)δ-nuclear factor kappalight- chain-enhancer of activated B cells (NF-κB) pathway and directly inducing NF-kB protein expression. Importantly, IngB has a synergistic effect with JQ1, a BET bromodomain inhibitor, in latent HIV reactivation. Conclusions: IngB is a new promising compound to activate latent HIV reservoirs. Our data suggest that formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.",
keywords = "HIV latency, Ingenol ester, JQ1, NF-κB, Protein kinase C",
author = "Guochun Jiang and Mendes, {Erica A.} and Philip Keiser and Sumathi Sankaran-Walters and Yuyang Tang and Weber, {Mariana G.} and Melcher, {Greg P.} and Thompson, {George R.} and Amilcar Tanuri and Pianowski, {Luiz F.} and Wong, {Joseph K.} and Satya Dandekar",
year = "2014",
month = "7",
day = "17",
doi = "10.1097/QAD.0000000000000289",
language = "English (US)",
volume = "28",
pages = "1555--1566",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling

AU - Jiang, Guochun

AU - Mendes, Erica A.

AU - Keiser, Philip

AU - Sankaran-Walters, Sumathi

AU - Tang, Yuyang

AU - Weber, Mariana G.

AU - Melcher, Greg P.

AU - Thompson, George R.

AU - Tanuri, Amilcar

AU - Pianowski, Luiz F.

AU - Wong, Joseph K.

AU - Dandekar, Satya

PY - 2014/7/17

Y1 - 2014/7/17

N2 - Objective: Although HAART effectively suppresses viral replication, it fails to eradicate latent viral reservoirs. The 'shock and kill' strategy involves the activation of HIV from latent reservoirs and targeting them for eradication. Our goal was to develop new approaches for activating HIV from latent reservoirs. Design: We investigated capacity of Ingenol B (IngB), a newly modified derivative of Ingenol ester that was originally isolated from a Brazilian plant in Amazon, for its capacity and mechanisms of HIV reactivation. Methods: Reactivation of HIV-1 by IngB was evaluated in J-Lat A1 cell culture model of HIV latency as well as in purified primary CD4+ T cells from long-term HAART-treated virologically-suppressed HIV-infected individuals. The underlining molecular mechanisms of viral reactivation were investigated using flow cytometry, RT-qPCR and chromatin immunoprecipitation. Results: IngB is highly effective in reactivating HIV in J-Lat A1 cells with relatively low cellular toxicity. It is also able to reactivate latent HIV in purified CD4 + T cells from HAART-treated HIV-positive individuals ex vivo. Our data show that IngB may reactivate HIV expression by both activating protein kinase C (PKC)δ-nuclear factor kappalight- chain-enhancer of activated B cells (NF-κB) pathway and directly inducing NF-kB protein expression. Importantly, IngB has a synergistic effect with JQ1, a BET bromodomain inhibitor, in latent HIV reactivation. Conclusions: IngB is a new promising compound to activate latent HIV reservoirs. Our data suggest that formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.

AB - Objective: Although HAART effectively suppresses viral replication, it fails to eradicate latent viral reservoirs. The 'shock and kill' strategy involves the activation of HIV from latent reservoirs and targeting them for eradication. Our goal was to develop new approaches for activating HIV from latent reservoirs. Design: We investigated capacity of Ingenol B (IngB), a newly modified derivative of Ingenol ester that was originally isolated from a Brazilian plant in Amazon, for its capacity and mechanisms of HIV reactivation. Methods: Reactivation of HIV-1 by IngB was evaluated in J-Lat A1 cell culture model of HIV latency as well as in purified primary CD4+ T cells from long-term HAART-treated virologically-suppressed HIV-infected individuals. The underlining molecular mechanisms of viral reactivation were investigated using flow cytometry, RT-qPCR and chromatin immunoprecipitation. Results: IngB is highly effective in reactivating HIV in J-Lat A1 cells with relatively low cellular toxicity. It is also able to reactivate latent HIV in purified CD4 + T cells from HAART-treated HIV-positive individuals ex vivo. Our data show that IngB may reactivate HIV expression by both activating protein kinase C (PKC)δ-nuclear factor kappalight- chain-enhancer of activated B cells (NF-κB) pathway and directly inducing NF-kB protein expression. Importantly, IngB has a synergistic effect with JQ1, a BET bromodomain inhibitor, in latent HIV reactivation. Conclusions: IngB is a new promising compound to activate latent HIV reservoirs. Our data suggest that formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.

KW - HIV latency

KW - Ingenol ester

KW - JQ1

KW - NF-κB

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=84904718063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904718063&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000289

DO - 10.1097/QAD.0000000000000289

M3 - Article

C2 - 24804860

AN - SCOPUS:84904718063

VL - 28

SP - 1555

EP - 1566

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -